

RECEIVED

AUG 23 2001

AUG 22 2001

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC8626CMAS	SERIAL NUMBER TECHNO CENTER 1600/2900 09803428
		APPLICANT William Curatolo, et al.	
		FILING DATE March 9, 2001	GROUP 1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Jane	4	5	1	7	3	5	9	5/14/85	Kobrehel et al.	C07H	17/08	
	4	4	7	4	7	6	8	10/2/84	Bright	A61K	31/71	
	4	9	6	3	5	3	1	10/16/90	Remington	A61K	31/70	
	4	7	9	2	4	4	8	12/20/88	Ranade, G. R.	424	438	
	4	5	2	2	6	2	5	6/11/85	Edgre, D.	604	892	
	4	9	6	8	5	0	7	11/6/90	Zentner, G. M., et al.	424	465	
	5	7	4	7	0	5	8	5/5/98	Tipton, et al.	424	423	
	5	7	0	5	1	9	0	1/6/98	Borad, et al.	424	465	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
												YES NO
✓	0	1	0	9	2	5	3	10/14/87	EP	C07H	17/00	
✓	8	9	0	2	2	7	1	3/23/89	WO	A61K	31/70	
✓	0	3	0	7	1	2	8	3/15/89	EP	A61K	31/71	
✓	9	5	0	9	6	0	1	4/13/95	WO	A61K	7/16	
✓	9	1	1	7	7	4	4	11/28/91	WO	A61K	9/22	
	0	2	9	8	6	5	0	1/11/89	EPO	C07H	17/02	
✓	9	4	1	2	1	5	9	6/9/94	WO International	A61K	9/28	
✓	9	4	0	0	1	1	2	1/6/94	WO	A61K	9/22	
	9	1	0	1	1	3	1	2/7/91	WO	A61K	9/22	
✓	9	0	0	9	1	6	8	8/23/90	WO	A61K	9/22	
✓	0	3	7	8	4	0	4	7/18/90	EP	A61K	31/00	
✓	0	0	8	0	3	4	1	7/1/83	EP	A61K	9/22	
✓	0	5	8	2	3	9	6	2/9/94	EP	A61K	31/71	
✓	2	0	6	6	0	7	0	7/8/81	GB	A61K	9/36	
✓	2	0	9	1	0	9	7	7/28/82	GB	A61K	9/36	

RECEIVED

AUG 23 2001

AUG 22 2001

PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC8626CMAS	SEARCH CENTER 0980362800
		APPLICANT William Curatolo, et al.	09803628
		FILING DATE March 9, 2001	GROUP 1616

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

<i>RW</i>	<input checked="" type="checkbox"/>	Martindale, The Extra Pharmacopoeia, 30 th , The Pharm. Press, London, 1963, Page 1197
	<input checked="" type="checkbox"/>	PDR, 48 th , Med. L994, N.Y. Page 1789
	<input checked="" type="checkbox"/>	The Merck Index, 11 th , Merck & Co., N.Y., 1989, Page 146 Remington Pharmaceutical Science, 16 th Merck Pub.
	<input checked="" type="checkbox"/>	Farmacia Practica de Remington, second Spanish edition, UTEHA, Mexico, 1965, Pages 471 and 525
	<input checked="" type="checkbox"/>	Laegemiddelkataloget, Copenhagen 1992, page 229, and page 356
	<input checked="" type="checkbox"/>	Farmaceuten, No. 12, 1990, page 402-405
	<input checked="" type="checkbox"/>	Hon-Leung Lee et al., "Drug Properties Influencing The Design of Sustained or Controlled Release Drug Delivery"
	<input checked="" type="checkbox"/>	Chapters 88, 90, and 91 from Remington Pharmaceutical Science, 16 th Merck Pub., Co., Pennsylvania (1980), PP. 1535, 1585, 1594.
	<input checked="" type="checkbox"/>	Scott Hopkins, The American Journal of Medicine, Volume 91, (Suppl 3A) September 12, 1991, 3A-40S-3A-45S
	<input checked="" type="checkbox"/>	J. R. Cardinal, Plenum Publishing Corp., 1984, Drug Release From Matrix Devices
	<input checked="" type="checkbox"/>	Richard H. Drew, Pharmacotherapy, Volume 12, Number 3, 1992, pgs 162-173
	<input checked="" type="checkbox"/>	Chem. Abstr., Yoshitomi, H., et al., V 119, No. 8, p. 496, abst. no. 79946v, "Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase I. In vitro Disintegration Test"
<i>RW</i>	<input checked="" type="checkbox"/>	Farmaceutisk Tidende, No. 35/36, 1988, page 537-548

EXAMINER

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE